Impact of the CFTR-Potentiator Ivacaftor on Airway Microbiota in Cystic Fibrosis Patients Carrying A G551D Mutation
Cédric Bernarde(Université de Bretagne Occidentale), Geneviève Héry-Arnaud, Georges Barbier(Ifremer), Marlène Keravec(Université de Bretagne Occidentale), Jérôme Mounier(Université de Bretagne Occidentale), G. Rault(ManRos Therapeutics (France)), Claude Férec(Université de Bretagne Occidentale), S. Gouriou(Université de Bretagne Occidentale)
Cited by 84
Related Papers
Modulating Innate and Adaptive Immunity by (R)-Roscovitine: Potential Therapeutic Opportunity in Cystic Fibrosis
|Journal of Innate Immunity|2016|5k
The origin of the major cystic fibrosis mutation (ΔF508) in European populations
|Nature Genetics|1994|347
Antifungal Microbial Agents for Food Biopreservation—A Review
|Microorganisms|2017|336
Diversity and Control of Spoilage Fungi in Dairy Products: An Update
|Microorganisms|2017|289
Microbial Interactions within a Cheese Microbial Community
|Applied and Environmental Microbiology|2007|254